StreetInsider.com News Articles

Biomerica receives UK regulatory approval for H. pylori diagnostic test

Thu, 05 Mar 2026 08:22:44 -0500

Biomerica Inc. (NASDAQ: BMRA) announced it received registration from the UK Medicines & Healthcare products Regulatory Agency for its hp+detect™ diagnostic test that detects Helicobacter pylori bacteria. The approval allows the company to commercially market the product to laboratories throughout Great Britain.

The hp+detect™ test identifies H. pylori bacteria, which the World Health Organization designates as a Class 1 carcinogen. The bacteria affects an estimated 35% of the U.S. population and 45% of the population in Europe's five largest countries, according to the company's statement.

H. pylori infection represents the strongest known risk factor for gastric cancer, which ranks as the third

Biomerica receives UK regulatory approval for H. pylori diagnostic test

Thu, 05 Mar 2026 08:22:44 -0500

H. pylori infection represents the strongest known risk factor for gastric cancer, which ranks as the third

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain

Thu, 05 Mar 2026 08:19:00 -0500

UK Market Entry: MHRA registration authorizes hp+detect™ for commercial sale in Great Britain
Active Commercialization: Biomerica is in active discussions with UK partners to access the diagnostic laboratory market and expects to provide further updates as agreements are finalized.
Disease Burden: The WHO designates H. pylori as a Class 1 carcinogen and lists it among the 16 antibiotic-resistant bacteria posing the greatest global health threat — underscoring the clinical need for accurate diagnostics.

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic and therapeutic products, today announced

Form S-8 BIOMERICA INC

Fri, 27 Feb 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260227/26083594.html

Form S-8 BIOMERICA INC

Fri, 27 Feb 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260227/26083594.html

Biomerica reports real-world data showing IBS therapy effectiveness

Thu, 26 Feb 2026 08:20:11 -0500

Biomerica Inc. (NASDAQ: BMRA) announced results from a real-world study of its inFoods IBS therapy, showing that 59.4% of patients achieved at least a 30% reduction in abdominal pain and 68.1% achieved similar reductions in bloating.

The analysis included 69 patients who completed an 8-week study protocol. Among 62 patients who tested positive for food sensitivities, mean abdominal pain scores decreased 34.6% from baseline to 8 weeks, while bloating scores declined 41.7% over the same period.

The company used the FDA-recognized responder endpoint of at least 30% improvement in weekly average symptom scores, consistent with standards applied to clinical trials for IBS

Biomerica reports real-world data showing IBS therapy effectiveness

Thu, 26 Feb 2026 08:20:11 -0500

The company used the FDA-recognized responder endpoint of at least 30% improvement in weekly average symptom scores, consistent with standards applied to clinical trials for IBS

Biomerica reports real-world data showing IBS therapy effectiveness

Thu, 26 Feb 2026 08:20:11 -0500

The company used the FDA-recognized responder endpoint of at least 30% improvement in weekly average symptom scores, consistent with standards applied to clinical trials for IBS

Biomerica reports real-world data showing IBS therapy effectiveness

Thu, 26 Feb 2026 08:20:11 -0500

The company used the FDA-recognized responder endpoint of at least 30% improvement in weekly average symptom scores, consistent with standards applied to clinical trials for IBS

Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy